Wendy E. Boertien

Glomerular and Tubular Damage Markers Are Elevated in Patients With Diabetes

Ferdau L. Nauta, Wendy E. Boertien, Stephan J. L. Bakker et al. · Diabetes Care · 2011 · 238 citations · Full text

Vasopressin, Copeptin, and Renal Concentrating Capacity in Patients with Autosomal Dominant Polycystic Kidney Disease without Renal Impairment

Debbie Zittema, Wendy E. Boertien, André P. van Beek et al. · Clinical Journal of the American Society of Nephrology · 2012 · 117 citations

Association of Urinary Biomarkers With Disease Severity in Patients With Autosomal Dominant Polycystic Kidney Disease: A Cross-sectional Analysis

Esther Meijer, Wendy E. Boertien, Ferdau L. Nauta et al. · American Journal of Kidney Diseases · 2010 · 105 citations

Glomerulonephritis, Urology, Renal Disease +11

Relationship of Copeptin, a Surrogate Marker for Arginine Vasopressin, With Change in Total Kidney Volume and GFR Decline in Autosomal Dominant Polycystic Kidney Disease: Results From the CRISP Cohort

Wendy E. Boertien, Esther Meijer, Jie Li et al. · American Journal of Kidney Diseases · 2012 · 104 citations · Full text

Urology, Arginine Vasopressin, Renal Function +10

Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease

Wendy E. Boertien, Esther Meijer, Paul E. de Jong et al. · Kidney International · 2013 · 91 citations

Urology, Renal Function, Medicine +8